

# GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Date: 29<sup>th</sup> June, 2021

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai-400001  
Email ID: [corp.relations@bseindia.com](mailto:corp.relations@bseindia.com)

**Ref: Genomic Valley Biotech Limited (539206/ GVBL)**

**Sub: Outcomes of Board Meeting**

1. Intimation and disclosure under Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Audited Financial Results and Independent Auditor's Report for the quarter and year ended 31.03.2021

Dear Sir/ Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of Genomic Valley Biotech Limited ("Company") in its meeting held today approved the Audited Financial Results (Standalone) for the Quarter and Year ended 31<sup>st</sup> March, 2021 of the Company as per Indian Accounting Standards (IND-AS) along with the Independent Auditor's Report. Copy of the results along with the Independent Auditor's Report of Statutory Auditors is attached herewith for your perusal.

The above information will also be available on the Company's Website, [www.genomicvalley.com](http://www.genomicvalley.com).


The meeting of the Board of Directors commenced on 11:45 A.M. and concluded at 05:00 P.M.

Please take the above on records.

Thanking you.

Yours sincerely

For Genomic Valley Biotech Limited



Yogesh Agrawal  
Managing Director  
DIN: 01165288  
Add: G-74, Pushkar Enclave,  
Paschim Vihar Delhi - 110063

**GENOMIC VALLEY BIOTECH LIMITED**

Regd. Off: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHERI,


TEHSIL-BAHADURGARH, DISTT-JHAJJAR, HARYANA-124507

CIN: L01122HR1994PLC033029

Statement of Standalone Audited Financials Results for the quarter and year ended March 31, 2021

In Rs.

| Sr. No. | Particular  | For the quarter ended |                  |                  | For the year ended |                  |
|---------|---|-----------------------|------------------|------------------|--------------------|------------------|
|         |   | 31-Mar-21             | 31-Dec-20        | 31-Mar-20        | 31-Mar-21          | 31-Mar-20        |
|         |   | Audited               | Un-Audited       | Audited          | Audited            | Audited          |
| I       | Revenue From Operations   | 216,895               | 916,620          | 2,972,500        | 2,080,805          | 8,465,629        |
| II      | Other Income  | 29,221                | -                | 15,000           | 29,221             | 140,869          |
| III     | <b>Total Revenue (I+II)</b>   | <b>246,116</b>        | <b>916,620</b>   | <b>2,987,500</b> | <b>2,110,026</b>   | <b>8,606,499</b> |
| IV      | <b>Expenses</b>   |                       |                  |                  |                    |                  |
|         | Cost of materials consumed  | 17,100                | 24,602           | 72,000           | 50,242             | 88,265           |
|         | Purchases of Stock-in-Trade   | -                     | -                | -                | -                  | -                |
|         | Changes in inventories of finished goods work-in-progress and Stock-in-Trade  | -                     | -                | -765,600         | 765,600            | -765,600         |
|         | Employee benefits expense   | 156,300               | 181,500          | 224,834          | 857,734            | 1,765,260        |
|         | Financial costs   | 1,774,570             | -                | 1,798,878        | 1,774,570          | 1,798,878        |
|         | Depreciation and amortization expense   | 447,806               | 481,439          | 505,624          | 1,892,123          | 1,785,803        |
|         | Other expenses  | 1,113,716             | 365,342          | 347,959          | 1,787,900          | 1,876,582        |
|         | <b>Total Expenses (IV)</b>  | <b>3,509,492</b>      | <b>1,052,883</b> | <b>2,183,695</b> | <b>7,128,169</b>   | <b>6,549,188</b> |
| V       | <b>Profit / (Loss) before exceptional item and tax (III-IV)</b>   | <b>-3,263,376</b>     | <b>-136,263</b>  | <b>803,805</b>   | <b>-5,018,143</b>  | <b>2,057,310</b> |
| VI      | <b>Exceptional Item</b>   |                       |                  |                  |                    |                  |
| VII     | <b>Profit/loss before Tax (V-VI)</b>  | <b>-3,263,376</b>     | <b>-136,263</b>  | <b>803,805</b>   | <b>-5,018,143</b>  | <b>2,057,310</b> |
| VIII    | <b>Tax expenses</b>   |                       |                  |                  |                    |                  |
|         | (1) Current Tax   |                       |                  |                  |                    |                  |
|         | (2) Deferred Tax  | 572,371               | -                | -802,616         | 572,371            | -802,616         |
| IX      | <b>Profit/ (Loss) for the period from continuing operations (VII-VIII)</b>  | <b>-3,835,747</b>     | <b>-136,263</b>  | <b>1,606,422</b> | <b>-5,590,514</b>  | <b>2,859,927</b> |
| X       | <b>Profit/ (Loss) from discontinued operations</b>  |                       |                  |                  |                    |                  |
| XI      | <b>Tax expense of discontinued operations</b>   |                       |                  |                  |                    |                  |
| XII     | <b>Profit/ (Loss) from discontinuing operations (after tax) (X-XI)</b>  |                       |                  |                  |                    |                  |
| XIII    | <b>Profit/Loss for the period (IX+XII)</b>  | <b>-3,835,747</b>     | <b>-136,263</b>  | <b>1,606,422</b> | <b>-5,590,514</b>  | <b>2,859,927</b> |
| XIV     | <b>Other Comprehensive Income</b>   |                       |                  |                  |                    |                  |
| A       | (i) Items that will not be reclassified to profit or loss   | -                     | -                | -                | -                  | -                |
|         | (ii) Income tax relating to items that will not be reclassified to profit or loss   | -                     | -                | -                | -                  | -                |
| B       | (i) Items that will be reclassified to profit or loss   | -                     | -                | -                | -                  | -                |
|         | (ii) Income tax relating to items that will be reclassified to profit or loss   | -                     | -                | -                | -                  | -                |
| XV      | <b>Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit/ (Loss) and other Comprehensive Income for the period)</b> | <b>-3,835,747</b>     | <b>-136,263</b>  | <b>1,606,422</b> | <b>-5,590,514</b>  | <b>2,859,927</b> |
| XVI     | <b>Paid up Equity Share Capital, Equity Share of ₹ 10/- each</b>  | <b>3,054,500</b>      | <b>3,054,500</b> | <b>3,054,500</b> | <b>3,054,500</b>   | <b>3,054,500</b> |
| XVII    | <b>Earning Per Equity Share (for continuing operation):</b>   |                       |                  |                  |                    |                  |
|         | 1) Basic  | -1.26                 | -0.04            | 0.53             | -1.83              | 0.94             |
|         | 2) Diluted  | -1.26                 | -0.04            | 0.53             | -1.83              | 0.94             |
| XVIII   | <b>Earning Per Equity Share (for discontinued operation):</b>   |                       |                  |                  |                    |                  |
|         | 1) Basic  | 0.00                  | 0.00             | 0.00             | 0.00               | 0.00             |
|         | 2) Diluted  | 0.00                  | 0.00             | 0.00             | 0.00               | 0.00             |
| XIX     | <b>Earning Per Equity Share (for discontinued &amp; continuing operations):</b>   |                       |                  |                  |                    |                  |
|         | 1) Basic  | -1.26                 | -0.04            | 0.53             | -1.83              | 0.94             |
|         | 2) Diluted  | -1.26                 | -0.04            | 0.53             | -1.83              | 0.94             |




**GENOMIC VALLEY BIOTECH LIMITED**

**REGD. OFF: 4 K.M. STONE, BERRI CHHARRA ROAD, P.O. TANDAHARI, TEHSIL BAHADURGARH, DISTT. JHAJJAR, HARYANA-124507**

**CIN: L01122HR1994PLC033029**

**CASH FLOW STATEMENT FOR THE PERIOD ENDED 31 March, 2021**

|           | Particulars  | Amount in INR      |                   |
|-----------|--|--------------------|-------------------|
|           |  | 31.03.2021         | 31.03.2020        |
| <b>A.</b> | <b>CASH FLOW FROM OPERATING ACTIVITIES</b>               |                    |                   |
|           | Net Profit As Statement Profit & Loss                    | -5,018,143         | 2,057,310         |
|           | <b>Adjustment For</b>                                    |                    |                   |
|           | Discount received  | -                  | -                 |
|           | Non-Operating Income                                     | -                  | -                 |
|           | Interest Income  | 151                | -21,851           |
|           | Loss on sale of assets                                   | -                  | -                 |
|           | Depreciation and Amortisation Expenses                   | 1,892,123          | 1,785,803         |
|           | <b>Operating Profit Before Change in Working Capital</b> | <b>-3,125,869</b>  | <b>3,821,262</b>  |
|           | <b>ADJUSTMENTS FOR WORKING CAPITAL:</b>                  |                    |                   |
|           | Increase/Decrease in Loans and Advances                  | 14,650,000         | -5,000,000        |
|           | Decrease/ (Increase) in Inventories                      | 1,239,623          | -52,182           |
|           | Increase/Decrease in Security Deposits                   | 150,000            | -                 |
|           | Increase/Decrease in Trade Receivables                   | 377,573            | -443,209          |
|           | Increase/Decrease in Other Current Assets                | 527,707            | -909,180          |
|           | Increase/Decrease in Current Liabilities                 | 1,028,228          | 6,957,383         |
|           | <b>CASH GENERATED FROM OPERATIONS</b>                    | <b>14,847,262</b>  | <b>4,374,074</b>  |
|           | Taxes Paid   |                    |                   |
|           | <b>Total (A)</b>   | <b>14,847,262</b>  | <b>4,374,074</b>  |
| <b>B.</b> | <b>CASH FLOW FROM INVESTING ACTIVITIES</b>               |                    |                   |
|           | Additions/Sales to fixed assets                          | -15,793,000        | -4,769,015        |
|           | Purchase/Sell of Investments                             | -                  | -                 |
|           | Discount received  | -                  | -                 |
|           | Non-Operating Income                                     | -                  | -                 |
|           | Interest Income  | -151               | 21,851            |
|           | <b>Total (B)</b>   | <b>-15,793,151</b> | <b>-4,747,164</b> |
| <b>C.</b> | <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>              |                    |                   |
|           | Proceeds from Borrowings                                 | 682,867            | -                 |
|           | Preliminary Expenses                                     | -                  | -                 |
|           | <b>Total (C)</b>   | <b>682,867</b>     | <b>-</b>          |
|           | <b>NET CASH FLOWS DURING THE YEAR (A+B+C)</b>            | <b>-263,022</b>    | <b>-373,090</b>   |
|           | <b>Cash and Cash Equivalents (Opening Balance)</b>       | <b>377,554</b>     | <b>750,644</b>    |
|           | <b>Cash and Cash Equivalents (Closing Balance)</b>       | <b>114,532</b>     | <b>377,554</b>    |




**Statement of Asset and Liabilities**

| Particulars                          | As at             |                   |
|--------------------------------------|-------------------|-------------------|
|                                      | 31/03/2021        | 31/03/2020        |
|                                      | Audited           | Audited           |
|                                      | Standalone        | Standalone        |
| <b>ASSETS</b>                        |                   |                   |
| <b>Non Current Assets</b>            |                   |                   |
| Property, plant and equipment        | 58,587,239        | 44,686,362        |
| Capital work in progress             | 4,879,339         | 4,879,339         |
| Other Intangible assets              | -                 | -                 |
| Intangible assets under development  | -                 | -                 |
| Financial assets                     | -                 | -                 |
| Investment                           | -                 | -                 |
| Loans                                | 10,950,000        | 25,600,000        |
| Security Deposits                    | 50,000            | 200,000           |
| Other financial assets               | -                 | -                 |
| Deferred tax assets (Net)            | 80,812            | 653,183           |
| Other non current assets             | -                 | -                 |
| <b>Total Non-Current Assets</b>      | <b>74,547,390</b> | <b>76,018,884</b> |
| <b>Current Assets</b>                |                   |                   |
| Inventories                          | -                 | 1,239,623         |
| Financial Assets:                    | -                 | -                 |
| Investments                          | -                 | -                 |
| Trade Receivables                    | 649,119           | 1,026,692         |
| Cash and Cash equivalents            | -                 | 319,100           |
| Other Balances with banks            | 114,532           | 58,454            |
| Loans                                | -                 | -                 |
| Other financial assets               | -                 | -                 |
| Other Current assets                 | 872,654           | 1,400,361         |
| <b>Total Current Assets</b>          | <b>1,636,305</b>  | <b>4,044,230</b>  |
| <b>Total Assets</b>                  | <b>76,183,694</b> | <b>80,063,114</b> |
| <b>EQUITY AND LIABILITIES</b>        |                   |                   |
| <b>Equity</b>                        |                   |                   |
| Equity Share Capital                 | 30,545,000        | 30,545,000        |
| Other Equity                         | 14,334,645        | 19,925,159        |
| <b>Total Equity</b>                  | <b>44,879,645</b> | <b>50,470,159</b> |
| <b>Non Current Liabilities</b>       |                   |                   |
| Financial liabilities                |                   |                   |
| Borrowings                           | 15,470,944        | 14,788,077        |
| Security Deposits                    | -                 | -                 |
| Other Financials liabilities         | -                 | -                 |
| Deferred tax liabilities (Net)       | -                 | -                 |
| Provisions                           | -                 | -                 |
| Other Non Current liabilities        | 7,120,000         | 7,120,000         |
| <b>Total Non Current Liabilities</b> | <b>22,590,944</b> | <b>21,908,077</b> |
| <b>Current Liabilities</b>           |                   |                   |
| Financial liabilities                |                   |                   |
| Borrowings                           | -                 | -                 |
| Trade Payables                       | 395,220           | 639,363           |
| Other Financials liabilities         | -                 | -                 |
| Provisions                           | 129,834           | 121,860           |
| Other Current liabilities            | 8,188,051         | 6,923,655         |
| <b>Total Current Liabilities</b>     | <b>8,713,105</b>  | <b>7,684,878</b>  |
| <b>TOTAL EQUITY AND LIABILITIES</b>  | <b>76,183,694</b> | <b>80,063,114</b> |


**Notes:**

- The above Financial Results were reviewed by the Members of Audit Committee and approved by the Board of Directors at their respective Meeting held on June 29, 2021 and the Statutory Auditors of the company have audited these financials results.
- The Company has adopted Indian Accounting Standards (Ind AS) notified by Ministry of Corporate Affairs from 1st April 2017, with a transition date 1st April 2016 and accordingly these financial Result have been prepared in accordance with the companies (Indian Accounting Standard) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India.
- Company's Business activity falls within a single business segment i.e. Horticulture in terms of Ind-AS 108 on Segment Reporting.
- Figures for the prior period have been regrouped and / or rearranged wherever considered necessary as per the revised format prescribed by SEBI under SEBI (LODR) Regulations, 2015 and amended as per the Schedule III of the Companies Act, 2013.
- The intangible asset namely "domain" will be ammortised over 4 years of useful life.



For and on behalf of the Board of Directors of  
Genomic Valley Biotech Limited

*Yogesh Agrawal*  
Yogesh Agrawal  
Managing Director  
DIN: 01165288  
Address: G-74, Pushkar Enclave,  
Paschim Vihar, New Delhi-110063




Place : Delhi  
Dated : 29/06/2021

21502310-AAAAX-5267

# GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berri Chhara Road, P.O. Tanda Heri, Tehsil  
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

June 29, 2021

To  
BSE Ltd.  
P. J. Towers, Da1a1 Street,  
Mumbai – 400001  
Scrip Code: 539206

**Sub: Declaration on Audit Reports with an unmodified opinion**

**Dear Sir/ Madam,**

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare that M/s ANDROS & CO., Chartered Accountants (Firm Registration No. 008976N), Statutory Auditors of the Company, have issued Audit Reports with an unmodified opinion on the Audited Standalone Financial Results of the Company for the year ended March 31, 2021.

Kindly take the same on record.

Thanking you.

**For Genomic Valley Biotech Limited**

**Yogesh Agrawal**  
Managing Director



**Lalit Shah**  
Chief Financial Officer

**Investor E-mail id: genomicvalley@gmail.com**

**ANDROS & CO.**  
**CHARTERED ACCOUNTANTS**

B.O. : 901, Pearls Omaxe, Plot B- 1,  
Distt Centre, Netaji Subhash Place  
Pitampura , New Delhi - 110034  
Phone : 011 -47060901,27357451  
Mobile : 9560438787  
E-mail :[cabhavukgarg@gmail.com](mailto:cabhavukgarg@gmail.com)

Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To  
Board of Directors of  
GENOMIC VALLEY BIOTECH LIMITED

1. We have audited the accompanying statement of quarterly Ind AS financial results of GENOMIC VALLEY BIOTECH LIMITED ('the Company) for the quarter ended March 31, 2021 and for the year ended March 31, 2021 ('the statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulation'), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ('the Circular'). The Ind AS financial results for quarter ended March 31, 2021 and year ended March 31, 2021 have been prepared on the basis of the Ind AS financial result for the nine month period ended December 31, 2020, the audited annual Ind As financial statement as at and for the year ended March 31, 2021, and the relevant requirements of Regulation and the Circular, which are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these financial results based on our review of the Ind AS financial results for the nine month period ended December 31, 2020 which was prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) 34 Interim Financial Reporting, specified under Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual Ind AS financial statements as at and for year ended march 31, 2021 and the relevant requirements of the Regulation and the Circular.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



3. In our opinion and to the best of our information and according to the explanations given to us, these quarterly Ind AS financial results as well as the year to date results:
- (i) are presented in accordance with the requirements of the Regulations read with the Circular, in this regard: and
  - (ii) give a true and fair view of the total comprehensive income (comprising net profit and other comprehensive income) and other financial information for the quarter ended March 31, 2021 and for the year ended March 31, 2021.
4. Further read with paragraph I above, we report that the figures for the quarter ended March 31, 2021 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2021 and the published year-to-date figures up to December 31, 2020, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph I above, as required under the Regulation and the Circular.

Date: 29.06.2021  
Place: New Delhi



For Andros & Co  
Chartered Accountant  
Firm No. 008976 N

*Bhavuk Garg*  
Bhavuk Garg  
Partner  
M. No. 502310

21502310-AAAAKW-7907